Přehled o publikaci
2022
Combinatorial pathway disruption is a powerful approach to delineate metabolic impacts of endocrine disruptors
BERNAL, Kevin, Charbel TOUMA, Chedi ERRADHOUANI, Talia BORONAT-BELDA, Lucas GAILLARD et. al.Základní údaje
Originální název
Combinatorial pathway disruption is a powerful approach to delineate metabolic impacts of endocrine disruptors
Autoři
BERNAL, Kevin, Charbel TOUMA, Chedi ERRADHOUANI, Talia BORONAT-BELDA, Lucas GAILLARD, Sara AL KASSIR, Helene LE MENTEC, Corinne MARTIN-CHOULY, Normand PODECHARD, Dominique LAGADIC-GOSSMANN, Sophie LANGOUET, Francois BRION, Anja KNOLL-GELLIDA, Patrick J. BABIN, Iva SOVADINOVÁ (203 Česká republika, domácí), Pavel BABICA (203 Česká republika, garant, domácí), Karine ANDREAU, Robert BAROUKI (250 Francie), Jan VONDRACEK, Paloma ALONSO-MAGDALENA, Etienne BLANC, Min Ji KIM a Xavier COUMOUL
Vydání
FEBS Letters, Hoboken, Wiley, 2022, 0014-5793
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Kód RIV
RIV/00216224:14310/22:00127970
Organizace
Přírodovědecká fakulta – Masarykova univerzita – Repozitář
UT WoS
000842558900001
EID Scopus
2-s2.0-85136484940
Klíčová slova anglicky
appetite; bisphenol; dioxin; inflammation; insulin resistance; microbiota; perfluorinated compounds; phthalate; TBT
Návaznosti
EF17_043/0009632, projekt VaV. 825712, interní kód Repo. 857560, interní kód Repo. RECETOX RI, velká výzkumná infrastruktura.
Změněno: 14. 6. 2025 00:50, RNDr. Daniel Jakubík
Anotace
V originále
The prevalence of metabolic diseases, such as obesity, diabetes, metabolic syndrome and chronic liver diseases among others, has been rising for several years. Epidemiology and mechanistic (in vivo, in vitro and in silico) toxicology have recently provided compelling evidence implicating the chemical environment in the pathogenesis of these diseases. In this review, we will describe the biological processes that contribute to the development of metabolic diseases targeted by metabolic disruptors, and will propose an integrated pathophysiological vision of their effects on several organs. With regard to these pathomechanisms, we will discuss the needs, and the stakes of evolving the testing and assessment of endocrine disruptors to improve the prevention and management of metabolic diseases that have become a global epidemic since the end of last century.